Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

qEEG Brain Signature of Depression & Neuromodulation-induced Recovery — Stella

Home/Major Depressive Diorder/qEEG Brain Signature of Depression & Neuromodulation-induced Recovery

View on ClinicalTrials.gov

Recruiting

Back to Major Depressive Diorder trials

qEEG Brain Signature of Depression & Neuromodulation-induced Recovery

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Canada

Sunnybrook Health Sciences Centre, North York, Ontario

Sunnybrook Health Sciences Centre, Toronto, Ontario

Key details

Phase

Early testing

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

Mitacs, iMediSync

Enrollment target

~100 participants

Started

January 2025

Primary completion

January 2027

Age range

18 Years – 80 Years

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.